In a recent clinical trial (NCT01730833), the research team conducted a phase I trial of nanoparticle albumin-conjugated paclitaxel (nab-PTX) in combination with trastuzumab (T-mab) and pertuzumab (P-mab) as a neoadjuvant chemotherapy for HER2-positive breast cancer. Here, ERBB2 is linked to breast cancer.